Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 376 participants.

Also called NCT07704684

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 376 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07704684
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07704684. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-28 (actual); primary completion 2025-08-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine
Condition
Essential Hypertension
Intervention (Drug)
Experimental: Sacubitril/Allisartan and Amlodipine Group
Intervention (Drug)
Active Comparator: Amlodipine Group
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07704684
Content hash
9fba9bbecb2f6ceee2253eeeb72ac2ad479718163074ffc81f2c8eecaad2e8b5